Recherche

Recherche2018-12-10T15:31:06-08:00

Le programme de recherche Can-SOLVE CKD comprend 18 projets multidisciplinaires couvrant la recherche en santé clinique et des populations et en sciences fondamentales.

Ces projets de recherche reposent sur trois sujets identifiés en collaboration avec les patients, le personnel de santé et les décideurs au cours des trois années de discussions sur les priorités à établir.:

Ensemble, les projets de recherche combleront les lacunes existantes au sujet des maladies rénales et de leurs traitements afin d’offrir de meilleurs résultats cliniques pour les patients. Le réseau Can-SOLVE CKD permettra de réaliser cette vision ambitieuse grâce à l’engagement des patients et en intégrant des découvertes isolées provenant des travaux canadiens exceptionnels en recherche fondamentale, clinique et translationnelle.

Rechercher des projets par thème

2018-08-01T16:26:40-07:00

Defining risk and personalizing treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Genetic screening and tests of kidney size can help nephrologists identify high-risk patients for new or experimental treatments, moderate-risk patients for close surveillance, and low-risk patients for reassurance. These tests, however, are costly and not widely available. We will confirm the usefulness of these tests and make them less costly, allowing for increased use in clinics.

2018-08-01T16:32:00-07:00

Clinical trials of promising re-purposed drugs for ADPKD

Advances in ADPKD research have identified a number of promising therapeutic drugs. Several of these drugs are re-purposed compounds that are currently approved for diseases other than ADPKD. We plan to perform two pilot control trials of two of these therapeutic drugs to test the impact on ADPKD patients and to evaluate their potential.

2019-02-09T09:34:23-08:00

DISCO: Dialysis Symptom Control

Gabapentin and pramipexole are commonly used drugs for several conditions and are known to reduce restless legs in patients who do not have kidney disease. The results of DISCO will determine whether gabapentin, pramipexole, or both should be offered to patients receiving dialysis who suffer from restless legs.

2019-05-14T13:34:16-07:00

EMPATHY: Patient-reported outcomes clustered RCT

Evidence suggests that patient-reported outcomes measures (PROMs) have a positive impact in clinical practice; however, the impact on health outcomes and experiences is not fully understood. This research aims to fill this gap by evaluating the impact of routinely measuring and reporting patient-reported experience and outcomes, clinical outcomes, and healthcare utilization.

Dernières publications

A Web-Based Self-Management Support Prototype for Adults With Chronic Kidney Disease (My Kidneys My Health): Co-Design and Usability Testing

Maoliosa Donald, Heather Beanlands, Sharon E Straus, Michelle Smekal, Sarah Gil, Meghan J Elliott, Gwen Herrington, Lori Harwood, Blair Waldvogel, Maria Delgado, Dwight Sparkes, Allison Tong, Allan Grill, Marta Novak, Matthew Thomas James, K Scott Brimble, Susan Samuel, Karen Tu, Janine Farragher, Brenda R Hemmelgarn. A Web-Based Self-Management Support Prototype for Adults With Chronic Kidney Disease (My Kidneys My Health): Co-Design and Usability Testing Originally published in JMIR Formative Research (http://formative.jmir.org), February 2021.

Kidney Check Point-of-Care Testing—Furthering Patient Engagement and Patient-Centered Care in Canada’s Rural and Remote Indigenous Communities: Program Report

Sarah Curtis, Heather Martin, Michelle DiNella, Barry Lavallee, Caroline Chartrand, Lorraine McLeod, Cathy Woods, Allison Dart, Navdeep Tangri, Claudio Rigatto, Paul Komenda. Kidney Check Point-of-Care Testing—Furthering Patient Engagement and Patient-Centered Care in Canada’s Rural and Remote Indigenous Communities: Program Report. Canadian Journal of Kidney Health and Disease. January 2021.

Go to Top